Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$11.43 USD
-0.25 (-2.14%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $11.43 0.00 (0.00%) 4:36 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.93 | -29.80 | -42.47 | -72.11 | -41.09 |
Depreciation/Amortization & Depletion | 0.20 | 1.23 | -1.23 | 0.29 | 0.34 |
Net Change from Assets/Liabilities | -3.92 | -3.43 | 14.44 | 13.36 | 7.49 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.22 | 3.53 | 4.03 | 4.05 | 4.74 |
Net Cash From Operating Activities | -22.43 | -28.47 | -25.23 | -54.41 | -28.53 |
Property & Equipment | -0.51 | -0.12 | -0.04 | -0.19 | -0.04 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.51 | -0.12 | -0.04 | -0.19 | -0.04 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.73 | 1.64 | 12.49 | 40.24 | 14.30 |
Issuance (Repayment) of Debt | 0.00 | -2.59 | -4.44 | -2.96 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 17.26 | 0.00 | 36.55 | 0.00 | -0.03 |
Net Cash from Financing Activities | 25.98 | -0.95 | 44.60 | 37.28 | 14.27 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 3.05 | -29.54 | 19.32 | -17.32 | -14.29 |
Cash at Beginning of Period | 32.73 | 62.27 | 42.95 | 60.27 | 74.56 |
Cash at End of Period | 35.78 | 32.73 | 62.27 | 42.95 | 60.27 |
Diluted Net EPS | -5.20 | -8.60 | -16.20 | -36.00 | -28.20 |
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -10.33 | -22.93 | -17.32 | -9.15 |
Depreciation/Amortization & Depletion | NA | 0.07 | 0.20 | 1.05 | 0.10 |
Net Change from Assets/Liabilities | NA | 2.61 | -3.92 | 4.33 | -1.12 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.00 | 4.22 | 2.23 | 2.10 |
Net Cash From Operating Activities | NA | -6.64 | -22.43 | -9.71 | -8.08 |
Property & Equipment | NA | -0.02 | -0.51 | -0.33 | -0.20 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.02 | -0.51 | -0.33 | -0.20 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | 8.73 | 25.98 | 25.98 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.09 | 17.26 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -0.09 | 25.98 | 25.98 | 25.98 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -6.76 | 3.05 | 15.94 | 17.70 |
Cash at Beginning of Period | NA | 35.78 | 32.73 | 32.73 | 32.73 |
Cash at End of Period | NA | 29.02 | 35.78 | 48.67 | 50.43 |
Diluted Net EPS | NA | -2.28 | -1.20 | -1.80 | -2.80 |